| Phase 01 trial |
|
Phase 0
|
NCT06479863 |
Aug 2024 → May 2027 expected |
idiopathic inflammatory myopathy, inclusion body myositis |
Austin Neuromuscular Center |
Recruiting
|
No outcome recorded
|
| Phase 15 trials |
|
Phase 1
|
NCT07230834 |
Jan 2026 → Jul 2028 expected |
dry age related macular degeneration |
Regeneron Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04940364 |
Aug 2021 → Jun 2022 |
— |
Regeneron Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04601844 |
Nov 2020 → Jul 2021 |
— |
Regeneron Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04491838 |
Aug 2020 → Mar 2021 |
— |
Regeneron Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03115996 |
May 2017 → Aug 2018 |
— |
Regeneron Pharmaceuticals |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT04811716 |
Jul 2021 → Oct 2022 |
paroxysmal nocturnal hemoglobinuria |
Regeneron Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04888507 |
Jul 2021 → May 2022 |
paroxysmal nocturnal hemoglobinuria |
Regeneron Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03946748 |
May 2019 → Jun 2021 |
paroxysmal nocturnal hemoglobinuria |
Regeneron Pharmaceuticals |
Completed
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT04209634 |
Jan 2020 → Nov 2021 |
protein-losing enteropathy |
Regeneron Pharmaceuticals |
Completed
|
No outcome recorded
|
| Phase 37 trials |
|
Phase 3
|
NCT07154745 |
Jun 2026 → Jan 2030 expected |
paroxysmal nocturnal hemoglobinuria |
Regeneron Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06541704 |
Oct 2024 → Nov 2027 expected |
dry age related macular degeneration |
Regeneron Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05744921 |
Mar 2023 → Feb 2029 expected |
paroxysmal nocturnal hemoglobinuria |
Regeneron Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05131204 |
Oct 2022 → Jul 2023 |
paroxysmal nocturnal hemoglobinuria |
Regeneron Pharmaceuticals |
Terminated
|
No outcome recorded
|
|
Phase 3
|
NCT05133531 |
Aug 2022 → Oct 2026 expected |
paroxysmal nocturnal hemoglobinuria |
Regeneron Pharmaceuticals |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05070858 |
Dec 2021 → Jul 2025 overdue |
generalized myasthenia gravis |
Regeneron Pharmaceuticals |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT04162470 |
Dec 2019 → Apr 2022 |
paroxysmal nocturnal hemoglobinuria |
Regeneron Pharmaceuticals |
Terminated
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT07142343 |
Mar 2026 → Feb 2030 expected |
— |
Regeneron Pharmaceuticals |
Recruiting
|
No outcome recorded
|
| Phase not stated3 trials |
| — |
NCT05232110 |
— |
protein-losing enteropathy |
Regeneron Pharmaceuticals |
Approved for marketing
|
No outcome recorded
|
| — |
NCT06003881 |
— |
protein-losing enteropathy |
Regeneron Pharmaceuticals |
Approved for marketing
|
No outcome recorded
|
| — |
NCT06028594 |
— |
paroxysmal nocturnal hemoglobinuria |
Regeneron Pharmaceuticals |
No longer available
|
No outcome recorded
|